The CCK‐8 assay indicated that the inhibitor of DDX3X (RK‐33) decreased the proliferation of DLBCL cell lines having TP53‐DDX3X co‐mutations. The gene discussed is DDX3X; the disease is diffuse large B-cell lymphoma.